Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.46)
# 950
Out of 5,090 analysts
106
Total ratings
47.62%
Success rate
6.3%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $5.23 | +110.53% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $4.09 | +46.70% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $3.38 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $485.21 | +8.20% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $53.82 | +67.24% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $457.26 | +4.97% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $51.95 | +5.87% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $122.42 | -34.65% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $10.98 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $722.83 | +40.42% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $340.33 | +19.00% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $464.56 | -52.64% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $15.33 | -34.77% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.73 | +13.54% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $58.85 | +22.34% | 1 | Apr 13, 2023 |
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.23
Upside: +110.53%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $4.09
Upside: +46.70%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.38
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $485.21
Upside: +8.20%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $53.82
Upside: +67.24%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $457.26
Upside: +4.97%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $51.95
Upside: +5.87%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $122.42
Upside: -34.65%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $10.98
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $722.83
Upside: +40.42%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $340.33
Upside: +19.00%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $464.56
Upside: -52.64%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $15.33
Upside: -34.77%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.73
Upside: +13.54%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $58.85
Upside: +22.34%